Covered recipient · General Payments record
JOHN RUBINO
Allopathic & Osteopathic Physicians Internal Medicine
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2023 · Entire year
$6,389.49
35 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2023 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Consulting Fee | $5,841.22 | 5 |
| Food and Beverage | $548.27 | 30 |
By paying entity
PY2023 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| PFIZER INC. | $5,884.43 | 8 |
| AbbVie Inc. | $101.87 | 5 |
| Novo Nordisk Inc | $91.86 | 5 |
| Amgen Inc. | $45.70 | 3 |
| Abbott Laboratories | $41.35 | 2 |
| AstraZeneca Pharmaceuticals LP | $31.26 | 2 |
| Otsuka America Pharmaceutical, Inc. | $25.96 | 1 |
| Lilly USA, LLC | $22.96 | 1 |
| Novartis Pharmaceuticals Corporation | $22.82 | 1 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | $22.55 | 1 |
| Bayer Healthcare Pharmaceuticals Inc. | $20.12 | 1 |
| GlaxoSmithKline, LLC. | $18.55 | 1 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $17.48 | 1 |
| Exact Sciences Corporation | $15.76 | 1 |
| Xeris Pharmaceuticals, Inc. | $14.07 | 1 |
| Amneal Pharmaceuticals LLC | $12.75 | 1 |
Page 1 of 1; records 1–35 of 35 matching records. This page contains 35 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
JOHN RUBINO
NPI 1962543280 · CMS profile ID 43312
Allopathic & Osteopathic Physicians / Internal Medicine
RALEIGH, NC
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 1 of 1; records 1–35 of 35 matching records. This page contains 35 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1962543280?year=2023&recipient=provider#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- JOHN RUBINO, NPI 1962543280, CMS profile ID 43312. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–35 of 35 matching records. This page contains 35 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1962543280?year=2023&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
- APA 7
- IndustryPayments. (2026). JOHN RUBINO, NPI 1962543280, CMS profile ID 43312. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–35 of 35 matching records. This page contains 35 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1962543280?year=2023&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
- Bluebook
- JOHN RUBINO, NPI 1962543280, CMS profile ID 43312, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–35 of 35 matching records. This page contains 35 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1962543280?year=2023&recipient=provider#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2023
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30
35 matching records · $6,389.49 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 1–35 of 35.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| PFIZER INC. | $17.91 | 12/15/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1050229195 | CMS |
| Lilly USA, LLC | $22.96 | 12/14/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1031510001 | CMS |
| Amgen Inc. | $14.88 | 12/06/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1019972483 | CMS |
| Abbott Laboratories | $16.81 | 11/28/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1019586299 | CMS |
| Amgen Inc. | $16.40 | 11/22/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1020605673 | CMS |
| AstraZeneca Pharmaceuticals LP | $17.88 | 11/01/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1014659173 | CMS |
| Otsuka America Pharmaceutical, Inc. | $25.96 | 10/18/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1014764903 | CMS |
| Amneal Pharmaceuticals LLC | $12.75 | 10/11/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1053530405 | CMS |
| AbbVie Inc. | $26.26 | 09/27/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 998724369 | CMS |
| Novo Nordisk Inc | $17.25 | 09/06/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1001792141 | CMS |
| Xeris Pharmaceuticals, Inc. | $14.07 | 08/30/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1056470115 | CMS |
| Novartis Pharmaceuticals Corporation | $22.82 | 08/23/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 992730679 | CMS |
| Novo Nordisk Inc | $21.30 | 08/09/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1001792161 | CMS |
| Amgen Inc. | $14.42 | 07/12/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1020605671 | CMS |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | $22.55 | 07/12/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1057489783 | CMS |
| AbbVie Inc. | $16.58 | 07/05/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 998724365 | CMS |
| AbbVie Inc. | $19.66 | 06/08/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 998724359 | CMS |
| GlaxoSmithKline, LLC. | $18.55 | 05/17/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1001355717 | CMS |
| Novo Nordisk Inc | $20.00 | 05/10/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1001792151 | CMS |
| AbbVie Inc. | $17.67 | 04/26/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 998724353 | CMS |
| PFIZER INC. | $14.97 | 04/20/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1050283505 | CMS |
| PFIZER INC. | $400.00 | 04/17/2023 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1050014413 | CMS |
| AbbVie Inc. | $21.70 | 04/12/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 998724347 | CMS |
| Exact Sciences Corporation | $15.76 | 04/05/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1026641277 | CMS |
| PFIZER INC. | $3,000.00 | 03/30/2023 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1049161737 | CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $17.48 | 03/29/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 996865223 | CMS |
| PFIZER INC. | $500.00 | 03/27/2023 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1049160835 | CMS |
| Bayer Healthcare Pharmaceuticals Inc. | $20.12 | 03/22/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1000324347 | CMS |
| Abbott Laboratories | $24.54 | 03/21/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1018771569 | CMS |
| PFIZER INC. | $10.33 | 03/10/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1049422011 | CMS |
| Novo Nordisk Inc | $16.08 | 02/23/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1001792121 | CMS |
| PFIZER INC. | $1,541.22 | 02/06/2023 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1049160829 | CMS |
| PFIZER INC. | $400.00 | 02/06/2023 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1049161743 | CMS |
| AstraZeneca Pharmaceuticals LP | $13.38 | 01/25/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1014166031 | CMS |
| Novo Nordisk Inc | $17.23 | 01/05/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1001792131 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $2,783,192.12 | 359 |
| PY2024 | Recipient | $66,231.01 | 15 |
| PY2024 | Principal investigator | $2,510,578.54 | 317 |
| PY2023 | Recipient | $6,417.61 | 4 |
| PY2023 | Principal investigator | $2,159,960.11 | 267 |
| PY2022 | Principal investigator | $2,441,546.83 | 286 |
| PY2021 | Principal investigator | $1,166,336.49 | 169 |
| PY2020 | Principal investigator | $1,326,147.90 | 192 |
| PY2019 | Principal investigator | $636,986.48 | 193 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2024
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
332 records in PY2024
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | ABBVIE INC. | $500.00 | 12/31/2024 | Non-covered Recipient Entity PMG RESEARCH INC DBA PMG RESEARCH OF MCFARLAND CLINIC | M23-714 Ubrelvy Menstrual Migraine | No dispute reported | 06/30/2026 | 1100765841 |
| Principal investigator 1 | ModernaTX, Inc. | $92,008.87 | 12/23/2024 | Non-covered Recipient Entity ACCELLACARE US INC | A PHASE 3, RANDOMIZED, OBSERVER-BLINDED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF MRNA-1403, A MULTIVALENT CANDIDATE VACCINE TO PREVENT NOROVIRUS ACUTE GASTROENTERITIS IN ADULTS 18 YEARS OF AGE | No dispute reported | 06/30/2026 | 1147191518 |
| Principal investigator 1 | ModernaTX, Inc. | $235,037.35 | 12/19/2024 | Non-covered Recipient Entity ACCELLACARE US INC | A PHASE 3, RANDOMIZED, OBSERVER-BLINDED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF MRNA-1403, A MULTIVALENT CANDIDATE VACCINE TO PREVENT NOROVIRUS ACUTE GASTROENTERITIS IN ADULTS 18 YEARS OF AGE | No dispute reported | 06/30/2026 | 1147191512 |
| Principal investigator 1 | BioNTech SE | $5,026.00 | 12/18/2024 | Non-covered Recipient Entity ACCELLACARE US INC | BNT163-01 | No dispute reported | 06/30/2026 | 1150667431 |
| Principal investigator 1 | H. Lundbeck A S | $451.00 | 12/18/2024 | Non-covered Recipient Entity ACCELLACARE US INC | INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, DOSE-FINDING TRIAL OF LU AG09222 FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH UNSUCCESSFUL PRIOR PREVENTIVE TREATMENTS | No dispute reported | 06/30/2026 | 1145888126 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $294.03 | 12/18/2024 | Non-covered Recipient Entity ACCELLACARE US INC | A Randomized, Double-Blind Study of The Efficacy and Safety of Trevogrumab, With or Without Garetosmab, in Addition to Semaglutide in Patients With Obesity | No dispute reported | 06/30/2026 | 1082449810 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $4,029.75 | 12/18/2024 | Non-covered Recipient Entity ACCELLACARE US INC | A Randomized, Double-Blind Study of The Efficacy and Safety of Trevogrumab, With or Without Garetosmab, in Addition to Semaglutide in Patients With Obesity | No dispute reported | 06/30/2026 | 1082449826 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,449.25 | 12/18/2024 | Non-covered Recipient Entity ACCELLACARE US INC | A Randomized, Double-Blind Study of The Efficacy and Safety of Trevogrumab, With or Without Garetosmab, in Addition to Semaglutide in Patients With Obesity | No dispute reported | 06/30/2026 | 1082449828 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $14,269.50 | 12/18/2024 | Non-covered Recipient Entity ACCELLACARE US INC | A Randomized, Double-Blind Study of The Efficacy and Safety of Trevogrumab, With or Without Garetosmab, in Addition to Semaglutide in Patients With Obesity | No dispute reported | 06/30/2026 | 1082449866 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,355.00 | 12/18/2024 | Non-covered Recipient Entity ACCELLACARE US INC | A Randomized, Double-Blind Study of The Efficacy and Safety of Trevogrumab, With or Without Garetosmab, in Addition to Semaglutide in Patients With Obesity | No dispute reported | 06/30/2026 | 1082449868 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $293.93 | 12/18/2024 | Non-covered Recipient Entity ACCELLACARE US INC | A Randomized, Double-Blind Study of The Efficacy and Safety of Trevogrumab, With or Without Garetosmab, in Addition to Semaglutide in Patients With Obesity | No dispute reported | 06/30/2026 | 1082449902 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,774.25 | 12/18/2024 | Non-covered Recipient Entity ACCELLACARE US INC | A Randomized, Double-Blind Study of The Efficacy and Safety of Trevogrumab, With or Without Garetosmab, in Addition to Semaglutide in Patients With Obesity | No dispute reported | 06/30/2026 | 1082449934 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $4,178.75 | 12/18/2024 | Non-covered Recipient Entity ACCELLACARE US INC | A Randomized, Double-Blind Study of The Efficacy and Safety of Trevogrumab, With or Without Garetosmab, in Addition to Semaglutide in Patients With Obesity | No dispute reported | 06/30/2026 | 1082449936 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,083.00 | 12/18/2024 | Non-covered Recipient Entity ACCELLACARE US INC | A Randomized, Double-Blind Study of The Efficacy and Safety of Trevogrumab, With or Without Garetosmab, in Addition to Semaglutide in Patients With Obesity | No dispute reported | 06/30/2026 | 1082449966 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $912.00 | 12/18/2024 | Non-covered Recipient Entity ACCELLACARE US INC | A Randomized, Double-Blind Study of The Efficacy and Safety of Trevogrumab, With or Without Garetosmab, in Addition to Semaglutide in Patients With Obesity | No dispute reported | 06/30/2026 | 1082449968 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,292.65 | 12/18/2024 | Non-covered Recipient Entity ACCELLACARE US INC | A Randomized, Double-Blind Study of The Efficacy and Safety of Trevogrumab, With or Without Garetosmab, in Addition to Semaglutide in Patients With Obesity | No dispute reported | 06/30/2026 | 1082450090 |
| Principal investigator 1 | H. Lundbeck A S | $28.75 | 12/12/2024 | Non-covered Recipient Entity ACCELLACARE US INC | INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, DOSE-FINDING TRIAL OF LU AG09222 FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH UNSUCCESSFUL PRIOR PREVENTIVE TREATMENTS | No dispute reported | 06/30/2026 | 1145888076 |
| Principal investigator 1 | H. Lundbeck A S | $194.50 | 12/12/2024 | Non-covered Recipient Entity ACCELLACARE US INC | INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, DOSE-FINDING TRIAL OF LU AG09222 FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH UNSUCCESSFUL PRIOR PREVENTIVE TREATMENTS | No dispute reported | 06/30/2026 | 1145888080 |
| Principal investigator 1 | ModernaTX, Inc. | $68.30 | 12/11/2024 | Non-covered Recipient Entity ACCELLACARE US INC | A PHASE 3, RANDOMIZED, OBSERVER-BLINDED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF MRNA-1403, A MULTIVALENT CANDIDATE VACCINE TO PREVENT NOROVIRUS ACUTE GASTROENTERITIS IN ADULTS 18 YEARS OF AGE | No dispute reported | 06/30/2026 | 1147191502 |
| Principal investigator 1 | BioNTech SE | $3,285.00 | 12/10/2024 | Non-covered Recipient Entity ACCELLACARE US INC | BNT163-01 | No dispute reported | 06/30/2026 | 1150667445 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $8,139.42 | 12/10/2024 | Non-covered Recipient Entity ACCELLACARE US INC | A Randomized, Double-Blind Study of The Efficacy and Safety of Trevogrumab, With or Without Garetosmab, in Addition to Semaglutide in Patients With Obesity | No dispute reported | 06/30/2026 | 1082448084 |
| Principal investigator 1 | ABBVIE INC. | $578.81 | 12/09/2024 | Non-covered Recipient Entity ACCELLACARE US INC | Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine | No dispute reported | 06/30/2026 | 1100760519 |
| Principal investigator 1 | ABBVIE INC. | $578.81 | 12/09/2024 | Non-covered Recipient Entity ACCELLACARE US INC | Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine | No dispute reported | 06/30/2026 | 1100760521 |
| Principal investigator 1 | ModernaTX, Inc. | $199.56 | 12/04/2024 | Non-covered Recipient Entity ACCELLACARE US INC | A PHASE 3, RANDOMIZED, OBSERVER-BLINDED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF MRNA-1403, A MULTIVALENT CANDIDATE VACCINE TO PREVENT NOROVIRUS ACUTE GASTROENTERITIS IN ADULTS 18 YEARS OF AGE | No dispute reported | 06/30/2026 | 1147191500 |
| Principal investigator 1 | BioNTech SE | $240.00 | 12/03/2024 | Non-covered Recipient Entity ACCELLACARE US INC | BNT163-01 | No dispute reported | 06/30/2026 | 1150667409 |
| Principal investigator 1 | BioNTech SE | $600.00 | 12/03/2024 | Non-covered Recipient Entity ACCELLACARE US INC | BNT163-01 | No dispute reported | 06/30/2026 | 1150667413 |
| Principal investigator 1 | BioNTech SE | $198.00 | 12/03/2024 | Non-covered Recipient Entity ACCELLACARE US INC | BNT163-01 | No dispute reported | 06/30/2026 | 1150667421 |
| Principal investigator 1 | BioNTech SE | $300.00 | 12/03/2024 | Non-covered Recipient Entity ACCELLACARE US INC | BNT163-01 | No dispute reported | 06/30/2026 | 1150667423 |
| Principal investigator 1 | BioNTech SE | $300.00 | 12/03/2024 | Non-covered Recipient Entity ACCELLACARE US INC | BNT163-01 | No dispute reported | 06/30/2026 | 1150667425 |
| Principal investigator 1 | BioNTech SE | $1,800.00 | 12/03/2024 | Non-covered Recipient Entity ACCELLACARE US INC | BNT163-01 | No dispute reported | 06/30/2026 | 1150667457 |
| Principal investigator 1 | BioNTech SE | $4,929.00 | 12/03/2024 | Non-covered Recipient Entity ACCELLACARE US INC | BNT163-01 | No dispute reported | 06/30/2026 | 1150667461 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $6,142.50 | 12/03/2024 | Non-covered Recipient Entity ACCELLACARE US INC | A Randomized, Double-Blind Study of The Efficacy and Safety of Trevogrumab, With or Without Garetosmab, in Addition to Semaglutide in Patients With Obesity | No dispute reported | 06/30/2026 | 1082446730 |
| Principal investigator 1 | ModernaTX, Inc. | $81.96 | 11/29/2024 | Non-covered Recipient Entity ACCELLACARE US INC | A PHASE 3, RANDOMIZED, OBSERVER-BLINDED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF MRNA-1403, A MULTIVALENT CANDIDATE VACCINE TO PREVENT NOROVIRUS ACUTE GASTROENTERITIS IN ADULTS 18 YEARS OF AGE | No dispute reported | 06/30/2026 | 1147191490 |
| Principal investigator 1 | ModernaTX, Inc. | $6,582.96 | 11/27/2024 | Non-covered Recipient Entity ACCELLACARE US INC | A PHASE 3, RANDOMIZED, OBSERVER-BLINDED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF MRNA-1403, A MULTIVALENT CANDIDATE VACCINE TO PREVENT NOROVIRUS ACUTE GASTROENTERITIS IN ADULTS 18 YEARS OF AGE | No dispute reported | 06/30/2026 | 1147191486 |
| Principal investigator 1 | BioNTech SE | $5,827.00 | 11/26/2024 | Non-covered Recipient Entity ACCELLACARE US INC | BNT163-01 | No dispute reported | 06/30/2026 | 1150667429 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $17,009.74 | 11/26/2024 | Non-covered Recipient Entity ACCELLACARE US INC | A Randomized, Double-Blind Study of The Efficacy and Safety of Trevogrumab, With or Without Garetosmab, in Addition to Semaglutide in Patients With Obesity | No dispute reported | 06/30/2026 | 1082445754 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $98.01 | 11/26/2024 | Non-covered Recipient Entity ACCELLACARE US INC | A Randomized, Double-Blind Study of The Efficacy and Safety of Trevogrumab, With or Without Garetosmab, in Addition to Semaglutide in Patients With Obesity | No dispute reported | 06/30/2026 | 1082445762 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,106.00 | 11/26/2024 | Non-covered Recipient Entity ACCELLACARE US INC | A Randomized, Double-Blind Study of The Efficacy and Safety of Trevogrumab, With or Without Garetosmab, in Addition to Semaglutide in Patients With Obesity | No dispute reported | 06/30/2026 | 1082445766 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,026.00 | 11/26/2024 | Non-covered Recipient Entity ACCELLACARE US INC | A Randomized, Double-Blind Study of The Efficacy and Safety of Trevogrumab, With or Without Garetosmab, in Addition to Semaglutide in Patients With Obesity | No dispute reported | 06/30/2026 | 1082445772 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,233.25 | 11/26/2024 | Non-covered Recipient Entity ACCELLACARE US INC | A Randomized, Double-Blind Study of The Efficacy and Safety of Trevogrumab, With or Without Garetosmab, in Addition to Semaglutide in Patients With Obesity | No dispute reported | 06/30/2026 | 1082445898 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $9,226.44 | 11/26/2024 | Non-covered Recipient Entity ACCELLACARE US INC | A Randomized, Double-Blind Study of The Efficacy and Safety of Trevogrumab, With or Without Garetosmab, in Addition to Semaglutide in Patients With Obesity | No dispute reported | 06/30/2026 | 1082445914 |
| Principal investigator 1 | BioNTech SE | $1,000.00 | 11/19/2024 | Non-covered Recipient Entity ACCELLACARE US INC | BNT163-01 | No dispute reported | 06/30/2026 | 1150667435 |
| Principal investigator 1 | BioNTech SE | $15,485.00 | 11/19/2024 | Non-covered Recipient Entity ACCELLACARE US INC | BNT163-01 | No dispute reported | 06/30/2026 | 1150667455 |
| Principal investigator 1 | ModernaTX, Inc. | $68.30 | 11/19/2024 | Non-covered Recipient Entity ACCELLACARE US INC | A PHASE 3, RANDOMIZED, OBSERVER-BLINDED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF MRNA-1403, A MULTIVALENT CANDIDATE VACCINE TO PREVENT NOROVIRUS ACUTE GASTROENTERITIS IN ADULTS 18 YEARS OF AGE | No dispute reported | 06/30/2026 | 1147191488 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,701.00 | 11/19/2024 | Non-covered Recipient Entity ACCELLACARE US INC | A Randomized, Double-Blind Study of The Efficacy and Safety of Trevogrumab, With or Without Garetosmab, in Addition to Semaglutide in Patients With Obesity | No dispute reported | 06/30/2026 | 1082444980 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $12,297.69 | 11/19/2024 | Non-covered Recipient Entity ACCELLACARE US INC | A Randomized, Double-Blind Study of The Efficacy and Safety of Trevogrumab, With or Without Garetosmab, in Addition to Semaglutide in Patients With Obesity | No dispute reported | 06/30/2026 | 1082445112 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $4,050.00 | 11/19/2024 | Non-covered Recipient Entity ACCELLACARE US INC | A Randomized, Double-Blind Study of The Efficacy and Safety of Trevogrumab, With or Without Garetosmab, in Addition to Semaglutide in Patients With Obesity | No dispute reported | 06/30/2026 | 1082445148 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,626.75 | 11/19/2024 | Non-covered Recipient Entity ACCELLACARE US INC | A Randomized, Double-Blind Study of The Efficacy and Safety of Trevogrumab, With or Without Garetosmab, in Addition to Semaglutide in Patients With Obesity | No dispute reported | 06/30/2026 | 1082445154 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $399.00 | 11/19/2024 | Non-covered Recipient Entity ACCELLACARE US INC | A Randomized, Double-Blind Study of The Efficacy and Safety of Trevogrumab, With or Without Garetosmab, in Addition to Semaglutide in Patients With Obesity | No dispute reported | 06/30/2026 | 1082445156 |
| Principal investigator 1 | BioNTech SE | $17,140.00 | 11/12/2024 | Non-covered Recipient Entity ACCELLACARE US INC | BNT163-01 | No dispute reported | 06/30/2026 | 1150667437 |
| Principal investigator 1 | H. Lundbeck A S | $22,289.00 | 11/12/2024 | Non-covered Recipient Entity ACCELLACARE US INC | INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, DOSE-FINDING TRIAL OF LU AG09222 FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH UNSUCCESSFUL PRIOR PREVENTIVE TREATMENTS | No dispute reported | 06/30/2026 | 1145887570 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $12,197.25 | 11/12/2024 | Non-covered Recipient Entity ACCELLACARE US INC | A Randomized, Double-Blind Study of The Efficacy and Safety of Trevogrumab, With or Without Garetosmab, in Addition to Semaglutide in Patients With Obesity | No dispute reported | 06/30/2026 | 1082444174 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $855.00 | 11/12/2024 | Non-covered Recipient Entity ACCELLACARE US INC | A Randomized, Double-Blind Study of The Efficacy and Safety of Trevogrumab, With or Without Garetosmab, in Addition to Semaglutide in Patients With Obesity | No dispute reported | 06/30/2026 | 1082444204 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $385.51 | 11/12/2024 | Non-covered Recipient Entity ACCELLACARE US INC | A Randomized, Double-Blind Study of The Efficacy and Safety of Trevogrumab, With or Without Garetosmab, in Addition to Semaglutide in Patients With Obesity | No dispute reported | 06/30/2026 | 1082444208 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $6,811.56 | 11/12/2024 | Non-covered Recipient Entity ACCELLACARE US INC | A Randomized, Double-Blind Study of The Efficacy and Safety of Trevogrumab, With or Without Garetosmab, in Addition to Semaglutide in Patients With Obesity | No dispute reported | 06/30/2026 | 1082444306 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $6,155.19 | 11/12/2024 | Non-covered Recipient Entity ACCELLACARE US INC | A Randomized, Double-Blind Study of The Efficacy and Safety of Trevogrumab, With or Without Garetosmab, in Addition to Semaglutide in Patients With Obesity | No dispute reported | 06/30/2026 | 1082444328 |
| Principal investigator 1 | BioNTech SE | $6,000.00 | 11/07/2024 | Non-covered Recipient Entity ACCELLACARE US INC | BNT163-01 | No dispute reported | 06/30/2026 | 1150667419 |
| Principal investigator 1 | BioNTech SE | $90.42 | 11/07/2024 | Non-covered Recipient Entity ACCELLACARE US INC | BNT163-01 | No dispute reported | 06/30/2026 | 1150667447 |
| Principal investigator 1 | BioNTech SE | $76.72 | 11/07/2024 | Non-covered Recipient Entity ACCELLACARE US INC | BNT163-01 | No dispute reported | 06/30/2026 | 1150667453 |
| Principal investigator 1 | BioNTech SE | $75.35 | 11/07/2024 | Non-covered Recipient Entity ACCELLACARE US INC | BNT163-01 | No dispute reported | 06/30/2026 | 1150667463 |
| Principal investigator 1 | BioNTech SE | $5,877.00 | 11/05/2024 | Non-covered Recipient Entity ACCELLACARE US INC | BNT163-01 | No dispute reported | 06/30/2026 | 1150667449 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $99,330.21 | 11/05/2024 | Non-covered Recipient Entity ACCELLACARE US INC | A Randomized, Double-Blind Study of The Efficacy and Safety of Trevogrumab, With or Without Garetosmab, in Addition to Semaglutide in Patients With Obesity | No dispute reported | 06/30/2026 | 1082443652 |
| Principal investigator 1 | BioNTech SE | $14,761.00 | 10/30/2024 | Non-covered Recipient Entity ACCELLACARE US INC | BNT163-01 | No dispute reported | 06/30/2026 | 1150667433 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $5,500.00 | 10/30/2024 | Non-covered Recipient Entity ACCELLACARE US INC | A Randomized, Double-Blind Study of The Efficacy and Safety of Trevogrumab, With or Without Garetosmab, in Addition to Semaglutide in Patients With Obesity | No dispute reported | 06/30/2026 | 1082442096 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $688.50 | 10/30/2024 | Non-covered Recipient Entity ACCELLACARE US INC | A Randomized, Double-Blind Study of The Efficacy and Safety of Trevogrumab, With or Without Garetosmab, in Addition to Semaglutide in Patients With Obesity | No dispute reported | 06/30/2026 | 1082442098 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,025.00 | 10/30/2024 | Non-covered Recipient Entity ACCELLACARE US INC | A Randomized, Double-Blind Study of The Efficacy and Safety of Trevogrumab, With or Without Garetosmab, in Addition to Semaglutide in Patients With Obesity | No dispute reported | 06/30/2026 | 1082442100 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,000.00 | 10/30/2024 | Non-covered Recipient Entity ACCELLACARE US INC | A Randomized, Double-Blind Study of The Efficacy and Safety of Trevogrumab, With or Without Garetosmab, in Addition to Semaglutide in Patients With Obesity | No dispute reported | 06/30/2026 | 1082442102 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $500.00 | 10/30/2024 | Non-covered Recipient Entity ACCELLACARE US INC | A Randomized, Double-Blind Study of The Efficacy and Safety of Trevogrumab, With or Without Garetosmab, in Addition to Semaglutide in Patients With Obesity | No dispute reported | 06/30/2026 | 1082442104 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $114.00 | 10/30/2024 | Non-covered Recipient Entity ACCELLACARE US INC | A Randomized, Double-Blind Study of The Efficacy and Safety of Trevogrumab, With or Without Garetosmab, in Addition to Semaglutide in Patients With Obesity | No dispute reported | 06/30/2026 | 1082442106 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,041.00 | 10/30/2024 | Non-covered Recipient Entity ACCELLACARE US INC | A Randomized, Double-Blind Study of The Efficacy and Safety of Trevogrumab, With or Without Garetosmab, in Addition to Semaglutide in Patients With Obesity | No dispute reported | 06/30/2026 | 1082442108 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $7,422.00 | 10/30/2024 | Non-covered Recipient Entity ACCELLACARE US INC | A Randomized, Double-Blind Study of The Efficacy and Safety of Trevogrumab, With or Without Garetosmab, in Addition to Semaglutide in Patients With Obesity | No dispute reported | 06/30/2026 | 1082442110 |
| Principal investigator 1 | BioNTech SE | $14,304.00 | 10/22/2024 | Non-covered Recipient Entity ACCELLACARE US INC | BNT163-01 | No dispute reported | 06/30/2026 | 1150667411 |
| Principal investigator 1 | ModernaTX, Inc. | $204.90 | 10/22/2024 | Non-covered Recipient Entity ACCELLACARE US INC | A PHASE 3, RANDOMIZED, OBSERVER-BLINDED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF MRNA-1403, A MULTIVALENT CANDIDATE VACCINE TO PREVENT NOROVIRUS ACUTE GASTROENTERITIS IN ADULTS 18 YEARS OF AGE | No dispute reported | 06/30/2026 | 1147191472 |
| Principal investigator 1 | H. Lundbeck A S | $13.25 | 10/18/2024 | Non-covered Recipient Entity ACCELLACARE US INC | INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, DOSE-FINDING TRIAL OF LU AG09222 FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH UNSUCCESSFUL PRIOR PREVENTIVE TREATMENTS | No dispute reported | 06/30/2026 | 1145887444 |
| Principal investigator 1 | H. Lundbeck A S | $28.75 | 10/18/2024 | Non-covered Recipient Entity ACCELLACARE US INC | INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, DOSE-FINDING TRIAL OF LU AG09222 FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH UNSUCCESSFUL PRIOR PREVENTIVE TREATMENTS | No dispute reported | 06/30/2026 | 1145887448 |
| Principal investigator 1 | BioNTech SE | $11,712.00 | 10/15/2024 | Non-covered Recipient Entity ACCELLACARE US INC | BNT163-01 | No dispute reported | 06/30/2026 | 1150667459 |
| Principal investigator 1 | ModernaTX, Inc. | $399.12 | 10/14/2024 | Non-covered Recipient Entity ACCELLACARE US INC | A PHASE 3, RANDOMIZED, OBSERVER-BLINDED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF MRNA-1403, A MULTIVALENT CANDIDATE VACCINE TO PREVENT NOROVIRUS ACUTE GASTROENTERITIS IN ADULTS 18 YEARS OF AGE | No dispute reported | 06/30/2026 | 1147191470 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $500.00 | 10/11/2024 | Non-covered Recipient Entity ACCELLACARE US INC | A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA | No dispute reported | 06/30/2026 | 1127529657 |
| Principal investigator 1 | BioNTech SE | $97.27 | 10/10/2024 | Non-covered Recipient Entity ACCELLACARE US INC | BNT163-01 | No dispute reported | 06/30/2026 | 1150667415 |
| Principal investigator 1 | BioNTech SE | $97.27 | 10/10/2024 | Non-covered Recipient Entity ACCELLACARE US INC | BNT163-01 | No dispute reported | 06/30/2026 | 1150667417 |
| Principal investigator 1 | BioNTech SE | $474.42 | 10/10/2024 | Non-covered Recipient Entity ACCELLACARE US INC | BNT163-01 | No dispute reported | 06/30/2026 | 1150667427 |
| Principal investigator 1 | BioNTech SE | $15,690.00 | 10/10/2024 | Non-covered Recipient Entity ACCELLACARE US INC | BNT163-01 | No dispute reported | 06/30/2026 | 1150667443 |
| Principal investigator 1 | BioNTech SE | $528.00 | 10/10/2024 | Non-covered Recipient Entity ACCELLACARE US INC | BNT163-01 | No dispute reported | 06/30/2026 | 1150667451 |
| Principal investigator 1 | BioNTech SE | $11,851.00 | 10/04/2024 | Non-covered Recipient Entity ACCELLACARE US INC | BNT163-01 | No dispute reported | 06/30/2026 | 1150667439 |
| Principal investigator 1 | BioNTech SE | $14,581.00 | 10/04/2024 | Non-covered Recipient Entity ACCELLACARE US INC | BNT163-01 | No dispute reported | 06/30/2026 | 1150667441 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $392.00 | 10/04/2024 | Non-covered Recipient Entity ACCELLACARE US INC | A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA | No dispute reported | 06/30/2026 | 1127529659 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $349.00 | 10/02/2024 | Non-covered Recipient Entity ACCELLACARE US INC | A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA | No dispute reported | 06/30/2026 | 1127529661 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $16,073.05 | 09/25/2024 | Non-covered Recipient Entity ACCELLACARE US INC | A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA | No dispute reported | 06/30/2026 | 1127529663 |
| Principal investigator 1 | BioNTech SE | $817.89 | 09/24/2024 | Non-covered Recipient Entity ACCELLACARE US INC | BNT163-01 | No dispute reported | 06/30/2026 | 1150667369 |
| Principal investigator 1 | BioNTech SE | $16,203.00 | 09/24/2024 | Non-covered Recipient Entity ACCELLACARE US INC | BNT163-01 | No dispute reported | 06/30/2026 | 1150667371 |
| Principal investigator 1 | BioNTech SE | $75.35 | 09/24/2024 | Non-covered Recipient Entity ACCELLACARE US INC | BNT163-01 | No dispute reported | 06/30/2026 | 1150667383 |
| Principal investigator 1 | BioNTech SE | $76.72 | 09/24/2024 | Non-covered Recipient Entity ACCELLACARE US INC | BNT163-01 | No dispute reported | 06/30/2026 | 1150667385 |
| Principal investigator 1 | BioNTech SE | $205.50 | 09/24/2024 | Non-covered Recipient Entity ACCELLACARE US INC | BNT163-01 | No dispute reported | 06/30/2026 | 1150667387 |
| Recipient | Eli Lilly and Company | $63,117.00 | 09/24/2024 | Covered Recipient Physician | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF LEPODISIRAN ON THE REDUCTION OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN ADULTS WITH ELEVATED LIPOPROTEIN(A) WHO HAVE ESTABLISHED ATHEROSCLEROTIC CARDIOVASCULAR DISEASE OR ARE AT RISK FOR A FIRST CARDIOVASCULAR EVENT - ACCLAIM-LP(A) | No dispute reported | 06/30/2026 | 1137348063 |
| Recipient | Eli Lilly and Company | $1,508.00 | 09/24/2024 | Covered Recipient Physician | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, EVENT-DRIVEN STUDY TO INVESTIGATE THE EFFECT OF RETATRUTIDE ON THE INCIDENCE OF MAJOR ADVERSE CARDIOVASCULAR EVENTS AND THE DECLINE IN KIDNEY FUNCTION IN PARTICIPANTS WITH BODY MASS INDEX GREATER THAN 27 KG M2 AND ATHEROSCLEROTIC CARDIOVASCULAR DISEASE AND OR CHRONIC KIDNEY DISEASE | No dispute reported | 06/30/2026 | 1137348161 |
| Principal investigator 1 | H. Lundbeck A S | $80.00 | 09/24/2024 | Non-covered Recipient Entity ACCELLACARE US INC | INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, DOSE-FINDING TRIAL OF LU AG09222 FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH UNSUCCESSFUL PRIOR PREVENTIVE TREATMENTS | No dispute reported | 06/30/2026 | 1145887352 |
| Principal investigator 1 | H. Lundbeck A S | $313.00 | 09/24/2024 | Non-covered Recipient Entity ACCELLACARE US INC | INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, DOSE-FINDING TRIAL OF LU AG09222 FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH UNSUCCESSFUL PRIOR PREVENTIVE TREATMENTS | No dispute reported | 06/30/2026 | 1145887362 |
| Principal investigator 1 | H. Lundbeck A S | $700.00 | 09/24/2024 | Non-covered Recipient Entity ACCELLACARE US INC | INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, DOSE-FINDING TRIAL OF LU AG09222 FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH UNSUCCESSFUL PRIOR PREVENTIVE TREATMENTS | No dispute reported | 06/30/2026 | 1145887374 |
| Principal investigator 1 | H. Lundbeck A S | $73.00 | 09/24/2024 | Non-covered Recipient Entity ACCELLACARE US INC | INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, DOSE-FINDING TRIAL OF LU AG09222 FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH UNSUCCESSFUL PRIOR PREVENTIVE TREATMENTS | No dispute reported | 06/30/2026 | 1145887384 |
| Principal investigator 1 | BioNTech SE | $144.00 | 09/18/2024 | Non-covered Recipient Entity ACCELLACARE US INC | BNT163-01 | No dispute reported | 06/30/2026 | 1150667381 |
| Principal investigator 1 | BioNTech SE | $13,611.00 | 09/18/2024 | Non-covered Recipient Entity ACCELLACARE US INC | BNT163-01 | No dispute reported | 06/30/2026 | 1150667403 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $7,500.00 | 09/18/2024 | Non-covered Recipient Entity ACCELLACARE US INC | A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA | No dispute reported | 06/30/2026 | 1127527046 |
| Principal investigator 1 | BioNTech SE | $11,019.00 | 09/10/2024 | Non-covered Recipient Entity ACCELLACARE US INC | BNT163-01 | No dispute reported | 06/30/2026 | 1150667391 |
| Principal investigator 1 | BioNTech SE | $7,083.00 | 09/03/2024 | Non-covered Recipient Entity ACCELLACARE US INC | BNT163-01 | No dispute reported | 06/30/2026 | 1150667367 |
| Principal investigator 1 | BioNTech SE | $13,611.00 | 08/27/2024 | Non-covered Recipient Entity ACCELLACARE US INC | BNT163-01 | No dispute reported | 06/30/2026 | 1150667405 |
| Principal investigator 1 | BioNTech SE | $80.83 | 08/27/2024 | Non-covered Recipient Entity ACCELLACARE US INC | BNT163-01 | No dispute reported | 06/30/2026 | 1150667407 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $9,427.80 | 08/27/2024 | Non-covered Recipient Entity ACCELLACARE US INC | A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA | No dispute reported | 06/30/2026 | 1127529651 |
| Principal investigator 1 | BioNTech SE | $693.00 | 08/19/2024 | Non-covered Recipient Entity ACCELLACARE US INC | BNT163-01 | No dispute reported | 06/30/2026 | 1150667393 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $500.00 | 08/19/2024 | Non-covered Recipient Entity ACCELLACARE US INC | A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA | No dispute reported | 06/30/2026 | 1127527054 |
| Recipient | Regeneron Pharmaceuticals, Inc. | $13.40 | 08/19/2024 | Covered Recipient Physician | A Randomized, Double-Blind Study of The Efficacy and Safety of Trevogrumab, With or Without Garetosmab, in Addition to Semaglutide in Patients With Obesity | No dispute reported | 06/30/2026 | 1082396990 |
| Recipient | Regeneron Pharmaceuticals, Inc. | $28.77 | 08/19/2024 | Covered Recipient Physician | A Randomized, Double-Blind Study of The Efficacy and Safety of Trevogrumab, With or Without Garetosmab, in Addition to Semaglutide in Patients With Obesity | No dispute reported | 06/30/2026 | 1082396992 |
| Recipient | Regeneron Pharmaceuticals, Inc. | $31.03 | 08/19/2024 | Covered Recipient Physician | A Randomized, Double-Blind Study of The Efficacy and Safety of Trevogrumab, With or Without Garetosmab, in Addition to Semaglutide in Patients With Obesity | No dispute reported | 06/30/2026 | 1082396994 |
| Principal investigator 1 | BioNTech SE | $9,023.00 | 08/13/2024 | Non-covered Recipient Entity ACCELLACARE US INC | BNT163-01 | No dispute reported | 06/30/2026 | 1150667365 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $39.00 | 08/09/2024 | Non-covered Recipient Entity ACCELLACARE US INC | A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA | No dispute reported | 06/30/2026 | 1127529599 |
| Principal investigator 1 | BioNTech SE | $144.00 | 08/07/2024 | Non-covered Recipient Entity ACCELLACARE US INC | BNT163-01 | No dispute reported | 06/30/2026 | 1150667379 |
| Principal investigator 1 | BioNTech SE | $5,364.00 | 08/07/2024 | Non-covered Recipient Entity ACCELLACARE US INC | BNT163-01 | No dispute reported | 06/30/2026 | 1150667395 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $98.00 | 08/07/2024 | Non-covered Recipient Entity ACCELLACARE US INC | A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA | No dispute reported | 06/30/2026 | 1127529605 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $500.00 | 08/02/2024 | Non-covered Recipient Entity ACCELLACARE US INC | A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA | No dispute reported | 06/30/2026 | 1127527050 |
| Principal investigator 1 | BioNTech SE | $7,124.00 | 08/01/2024 | Non-covered Recipient Entity ACCELLACARE US INC | BNT163-01 | No dispute reported | 06/30/2026 | 1150667361 |
| Principal investigator 1 | BioNTech SE | $600.00 | 07/30/2024 | Non-covered Recipient Entity ACCELLACARE US INC | BNT163-01 | No dispute reported | 06/30/2026 | 1150667397 |
| Principal investigator 1 | Eli Lilly and Company | $118,766.00 | 07/30/2024 | Non-covered Recipient Entity PIEDMONT MEDICAL RESEARCH ASSOCIATES INC | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF LEPODISIRAN ON THE REDUCTION OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN ADULTS WITH ELEVATED LIPOPROTEIN(A) WHO HAVE ESTABLISHED ATHEROSCLEROTIC CARDIOVASCULAR DISEASE OR ARE AT RISK FOR A FIRST CARDIOVASCULAR EVENT - ACCLAIM-LP(A) | No dispute reported | 06/30/2026 | 1137365491 |
| Recipient | Regeneron Pharmaceuticals, Inc. | $15.10 | 07/26/2024 | Covered Recipient Physician | A Randomized, Double-Blind Study of The Efficacy and Safety of Trevogrumab, With or Without Garetosmab, in Addition to Semaglutide in Patients With Obesity | No dispute reported | 06/30/2026 | 1082396976 |
| Recipient | Regeneron Pharmaceuticals, Inc. | $15.10 | 07/26/2024 | Covered Recipient Physician | A Randomized, Double-Blind Study of The Efficacy and Safety of Trevogrumab, With or Without Garetosmab, in Addition to Semaglutide in Patients With Obesity | No dispute reported | 06/30/2026 | 1082396978 |
| Recipient | Regeneron Pharmaceuticals, Inc. | $44.50 | 07/26/2024 | Covered Recipient Physician | A Randomized, Double-Blind Study of The Efficacy and Safety of Trevogrumab, With or Without Garetosmab, in Addition to Semaglutide in Patients With Obesity | No dispute reported | 06/30/2026 | 1082396980 |
| Recipient | Regeneron Pharmaceuticals, Inc. | $60.40 | 07/26/2024 | Covered Recipient Physician | A Randomized, Double-Blind Study of The Efficacy and Safety of Trevogrumab, With or Without Garetosmab, in Addition to Semaglutide in Patients With Obesity | No dispute reported | 06/30/2026 | 1082396982 |
| Recipient | Regeneron Pharmaceuticals, Inc. | $70.01 | 07/26/2024 | Covered Recipient Physician | A Randomized, Double-Blind Study of The Efficacy and Safety of Trevogrumab, With or Without Garetosmab, in Addition to Semaglutide in Patients With Obesity | No dispute reported | 06/30/2026 | 1082396984 |
| Recipient | Regeneron Pharmaceuticals, Inc. | $233.63 | 07/26/2024 | Covered Recipient Physician | A Randomized, Double-Blind Study of The Efficacy and Safety of Trevogrumab, With or Without Garetosmab, in Addition to Semaglutide in Patients With Obesity | No dispute reported | 06/30/2026 | 1082396986 |
| Recipient | Regeneron Pharmaceuticals, Inc. | $305.89 | 07/26/2024 | Covered Recipient Physician | A Randomized, Double-Blind Study of The Efficacy and Safety of Trevogrumab, With or Without Garetosmab, in Addition to Semaglutide in Patients With Obesity | No dispute reported | 06/30/2026 | 1082396988 |
| Recipient | Regeneron Pharmaceuticals, Inc. | $32.57 | 07/25/2024 | Covered Recipient Physician | A Randomized, Double-Blind Study of The Efficacy and Safety of Trevogrumab, With or Without Garetosmab, in Addition to Semaglutide in Patients With Obesity | No dispute reported | 06/30/2026 | 1082396972 |
| Recipient | Regeneron Pharmaceuticals, Inc. | $128.98 | 07/25/2024 | Covered Recipient Physician | A Randomized, Double-Blind Study of The Efficacy and Safety of Trevogrumab, With or Without Garetosmab, in Addition to Semaglutide in Patients With Obesity | No dispute reported | 06/30/2026 | 1082396974 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $2,828.15 | 07/24/2024 | Non-covered Recipient Entity ACCELLACARE US INC | A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA | No dispute reported | 06/30/2026 | 1127529655 |
| Principal investigator 1 | BioNTech SE | $11,435.00 | 07/23/2024 | Non-covered Recipient Entity ACCELLACARE US INC | BNT163-01 | No dispute reported | 06/30/2026 | 1150667401 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $794.00 | 07/22/2024 | Non-covered Recipient Entity ACCELLACARE US INC | A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA | No dispute reported | 06/30/2026 | 1127529595 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $500.00 | 07/17/2024 | Non-covered Recipient Entity ACCELLACARE US INC | A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA | No dispute reported | 06/30/2026 | 1127529603 |
| Principal investigator 1 | BioNTech SE | $13,791.00 | 07/16/2024 | Non-covered Recipient Entity ACCELLACARE US INC | BNT163-01 | No dispute reported | 06/30/2026 | 1150667389 |
| Recipient | Regeneron Pharmaceuticals, Inc. | $626.63 | 07/12/2024 | Covered Recipient Physician | A Randomized, Double-Blind Study of The Efficacy and Safety of Trevogrumab, With or Without Garetosmab, in Addition to Semaglutide in Patients With Obesity | No dispute reported | 06/30/2026 | 1082396970 |
| Principal investigator 1 | BioNTech SE | $24,117.00 | 07/10/2024 | Non-covered Recipient Entity ACCELLACARE US INC | BNT163-01 | No dispute reported | 06/30/2026 | 1150667363 |
| Principal investigator 1 | BioNTech SE | $66.00 | 07/10/2024 | Non-covered Recipient Entity ACCELLACARE US INC | BNT163-01 | No dispute reported | 06/30/2026 | 1150667373 |
| Principal investigator 1 | BioNTech SE | $48.00 | 07/10/2024 | Non-covered Recipient Entity ACCELLACARE US INC | BNT163-01 | No dispute reported | 06/30/2026 | 1150667375 |
| Principal investigator 1 | BioNTech SE | $192.00 | 07/10/2024 | Non-covered Recipient Entity ACCELLACARE US INC | BNT163-01 | No dispute reported | 06/30/2026 | 1150667377 |
| Principal investigator 1 | PFIZER INC. | $86,310.00 | 07/04/2024 | Non-covered Recipient Entity Accellacare US Inc | A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER | No dispute reported | 06/30/2026 | 1131044809 |
| Principal investigator 1 | BioNTech SE | $9,675.00 | 07/02/2024 | Non-covered Recipient Entity ACCELLACARE US INC | BNT163-01 | No dispute reported | 06/30/2026 | 1150667399 |
| Principal investigator 1 | BioNTech SE | $19,016.00 | 06/25/2024 | Non-covered Recipient Entity ACCELLACARE US INC | BNT163-01 | No dispute reported | 06/30/2026 | 1150667323 |
| Principal investigator 1 | Eli Lilly and Company | $103,327.00 | 06/25/2024 | Non-covered Recipient Entity PIEDMONT MEDICAL RESEARCH ASSOCIATES INC | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, EVENT-DRIVEN STUDY TO INVESTIGATE THE EFFECT OF RETATRUTIDE ON THE INCIDENCE OF MAJOR ADVERSE CARDIOVASCULAR EVENTS AND THE DECLINE IN KIDNEY FUNCTION IN PARTICIPANTS WITH BODY MASS INDEX GREATER THAN 27 KG M2 AND ATHEROSCLEROTIC CARDIOVASCULAR DISEASE AND OR CHRONIC KIDNEY DISEASE | No dispute reported | 06/30/2026 | 1137364895 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $1,875.60 | 06/25/2024 | Non-covered Recipient Entity ACCELLACARE US INC | A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA | No dispute reported | 06/30/2026 | 1127529607 |
| Principal investigator 1 | Novo Nordisk AS | $16,432.13 | 06/21/2024 | Non-covered Recipient Entity ACCELLACARE CLINICAL RESEARCH | NN9838-4608 | No dispute reported | 06/30/2026 | 1097185528 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $1,088.00 | 06/19/2024 | Non-covered Recipient Entity ACCELLACARE US INC | A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA | No dispute reported | 06/30/2026 | 1127527048 |
| Principal investigator 1 | BioNTech SE | $31,581.00 | 06/18/2024 | Non-covered Recipient Entity ACCELLACARE US INC | BNT163-01 | No dispute reported | 06/30/2026 | 1150667309 |
| Principal investigator 1 | BioNTech SE | $34,076.00 | 06/11/2024 | Non-covered Recipient Entity ACCELLACARE US INC | BNT163-01 | No dispute reported | 06/30/2026 | 1150667317 |
| Principal investigator 1 | ABBVIE INC. | $15,000.00 | 06/06/2024 | Non-covered Recipient Entity ACCELLACARE US INC | Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine | No dispute reported | 06/30/2026 | 1100722054 |
| Principal investigator 1 | BioNTech SE | $7,048.00 | 06/06/2024 | Non-covered Recipient Entity ACCELLACARE US INC | BNT163-01 | No dispute reported | 06/30/2026 | 1150667311 |
| Principal investigator 1 | BioNTech SE | $600.00 | 06/06/2024 | Non-covered Recipient Entity ACCELLACARE US INC | BNT163-01 | No dispute reported | 06/30/2026 | 1150667343 |
| Principal investigator 1 | PFIZER INC. | $23,316.00 | 06/06/2024 | Non-covered Recipient Entity Accellacare US Inc | A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER | No dispute reported | 06/30/2026 | 1131066398 |
| Principal investigator 1 | BioNTech SE | $44,654.00 | 05/28/2024 | Non-covered Recipient Entity ACCELLACARE US INC | BNT163-01 | No dispute reported | 06/30/2026 | 1150667315 |
| Principal investigator 1 | BioNTech SE | $96.00 | 05/28/2024 | Non-covered Recipient Entity ACCELLACARE US INC | BNT163-01 | No dispute reported | 06/30/2026 | 1150667339 |
| Principal investigator 1 | BioNTech SE | $144.00 | 05/23/2024 | Non-covered Recipient Entity ACCELLACARE US INC | BNT163-01 | No dispute reported | 06/30/2026 | 1150667305 |
| Principal investigator 1 | BioNTech SE | $556.22 | 05/23/2024 | Non-covered Recipient Entity ACCELLACARE US INC | BNT163-01 | No dispute reported | 06/30/2026 | 1150667313 |
| Principal investigator 1 | BioNTech SE | $600.00 | 05/23/2024 | Non-covered Recipient Entity ACCELLACARE US INC | BNT163-01 | No dispute reported | 06/30/2026 | 1150667333 |
| Principal investigator 1 | BioNTech SE | $768.57 | 05/23/2024 | Non-covered Recipient Entity ACCELLACARE US INC | BNT163-01 | No dispute reported | 06/30/2026 | 1150667347 |
| Principal investigator 1 | BioNTech SE | $264.00 | 05/23/2024 | Non-covered Recipient Entity ACCELLACARE US INC | BNT163-01 | No dispute reported | 06/30/2026 | 1150667349 |
| Principal investigator 1 | BioNTech SE | $48.00 | 05/23/2024 | Non-covered Recipient Entity ACCELLACARE US INC | BNT163-01 | No dispute reported | 06/30/2026 | 1150667353 |
| Principal investigator 1 | BioNTech SE | $100.00 | 05/23/2024 | Non-covered Recipient Entity ACCELLACARE US INC | BNT163-01 | No dispute reported | 06/30/2026 | 1150667357 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $5,092.95 | 05/22/2024 | Non-covered Recipient Entity ACCELLACARE US INC | A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA | No dispute reported | 06/30/2026 | 1127529665 |
| Principal investigator 1 | BioNTech SE | $26,164.00 | 05/21/2024 | Non-covered Recipient Entity ACCELLACARE US INC | BNT163-01 | No dispute reported | 06/30/2026 | 1150667337 |
| Principal investigator 1 | BioNTech SE | $43,143.00 | 05/21/2024 | Non-covered Recipient Entity ACCELLACARE US INC | BNT163-01 | No dispute reported | 06/30/2026 | 1150667351 |
| Principal investigator 1 | BioNTech SE | $991.00 | 05/14/2024 | Non-covered Recipient Entity ACCELLACARE US INC | BNT163-01 | No dispute reported | 06/30/2026 | 1150667331 |
| Principal investigator 1 | BioNTech SE | $54,923.00 | 05/14/2024 | Non-covered Recipient Entity ACCELLACARE US INC | BNT163-01 | No dispute reported | 06/30/2026 | 1150667355 |
| Principal investigator 1 | BioNTech SE | $53,010.00 | 05/14/2024 | Non-covered Recipient Entity ACCELLACARE US INC | BNT163-01 | No dispute reported | 06/30/2026 | 1150667359 |
| Principal investigator 1 | Eli Lilly and Company | $4,753.54 | 04/25/2024 | Non-covered Recipient Entity RHEUMATOLOGY CENTER OF HOUSTON | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF LEPODISIRAN ON THE REDUCTION OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN ADULTS WITH ELEVATED LIPOPROTEIN(A) WHO HAVE ESTABLISHED ATHEROSCLEROTIC CARDIOVASCULAR DISEASE OR ARE AT RISK FOR A FIRST CARDIOVASCULAR EVENT - ACCLAIM-LP(A) | No dispute reported | 06/30/2026 | 1137366187 |
| Principal investigator 1 | BioNTech SE | $35,893.00 | 04/23/2024 | Non-covered Recipient Entity ACCELLACARE US INC | BNT163-01 | No dispute reported | 06/30/2026 | 1150667319 |
| Principal investigator 1 | Eli Lilly and Company | $339.39 | 04/22/2024 | Non-covered Recipient Entity TRIANGLE MEDICAL RESEARCH ASSOCIATES LLC | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, EVENT-DRIVEN STUDY TO INVESTIGATE THE EFFECT OF RETATRUTIDE ON THE INCIDENCE OF MAJOR ADVERSE CARDIOVASCULAR EVENTS AND THE DECLINE IN KIDNEY FUNCTION IN PARTICIPANTS WITH BODY MASS INDEX GREATER THAN 27 KG M2 AND ATHEROSCLEROTIC CARDIOVASCULAR DISEASE AND OR CHRONIC KIDNEY DISEASE | No dispute reported | 06/30/2026 | 1137369036 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $6,421.05 | 04/22/2024 | Non-covered Recipient Entity ACCELLACARE US INC | A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA | No dispute reported | 06/30/2026 | 1127529601 |
| Principal investigator 1 | BioNTech SE | $12,900.00 | 04/16/2024 | Non-covered Recipient Entity ACCELLACARE US INC | BNT163-01 | No dispute reported | 06/30/2026 | 1150667341 |
| Principal investigator 1 | PFIZER INC. | $4,495.50 | 04/13/2024 | Non-covered Recipient Entity PMG Research Inc | A 26WEEK PHASE 2B 2PART RANDOMIZED DOUBLEBLIND PLACEBO CONTROLLED PARALLEL GROUP DOSERANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF06882961 ADMINISTRATION IN ADULTS WITH OBESITY | No dispute reported | 06/30/2026 | 1131089860 |
| Principal investigator 1 | BioNTech SE | $300.00 | 04/12/2024 | Non-covered Recipient Entity ACCELLACARE US INC | BNT163-01 | No dispute reported | 06/30/2026 | 1150667307 |
| Principal investigator 1 | BioNTech SE | $300.00 | 04/12/2024 | Non-covered Recipient Entity ACCELLACARE US INC | BNT163-01 | No dispute reported | 06/30/2026 | 1150667325 |
| Principal investigator 1 | BioNTech SE | $66.00 | 04/12/2024 | Non-covered Recipient Entity ACCELLACARE US INC | BNT163-01 | No dispute reported | 06/30/2026 | 1150667327 |
| Principal investigator 1 | BioNTech SE | $1,500.00 | 04/12/2024 | Non-covered Recipient Entity ACCELLACARE US INC | BNT163-01 | No dispute reported | 06/30/2026 | 1150667329 |
| Principal investigator 1 | BioNTech SE | $600.00 | 04/12/2024 | Non-covered Recipient Entity ACCELLACARE US INC | BNT163-01 | No dispute reported | 06/30/2026 | 1150667335 |
| Principal investigator 1 | BioNTech SE | $42,317.00 | 04/12/2024 | Non-covered Recipient Entity ACCELLACARE US INC | BNT163-01 | No dispute reported | 06/30/2026 | 1150667345 |
| Principal investigator 1 | PFIZER INC. | $73,077.91 | 04/12/2024 | Non-covered Recipient Entity Accellacare US Inc | A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER | No dispute reported | 06/30/2026 | 1131089854 |
| Principal investigator 1 | BioNTech SE | $25,332.00 | 04/04/2024 | Non-covered Recipient Entity ACCELLACARE US INC | BNT163-01 | No dispute reported | 06/30/2026 | 1150667321 |
| Principal investigator 1 | PFIZER INC. | $7,500.00 | 03/30/2024 | Non-covered Recipient Entity Accellacare US Inc | A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER | No dispute reported | 06/30/2026 | 1131098507 |
| Principal investigator 1 | PFIZER INC. | $6,496.20 | 03/27/2024 | Non-covered Recipient Entity PMG Research Inc | A 26WEEK PHASE 2B 2PART RANDOMIZED DOUBLEBLIND PLACEBO CONTROLLED PARALLEL GROUP DOSERANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF06882961 ADMINISTRATION IN ADULTS WITH OBESITY | No dispute reported | 06/30/2026 | 1131098501 |
| Principal investigator 1 | BioNTech SE | $41,232.00 | 03/26/2024 | Non-covered Recipient Entity ACCELLACARE US INC | BNT163-01 | No dispute reported | 06/30/2026 | 1150667289 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $21,812.00 | 03/25/2024 | Non-covered Recipient Entity ACCELLACARE US INC | A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA | No dispute reported | 06/30/2026 | 1127529653 |
| Principal investigator 1 | PFIZER INC. | $1,040.44 | 03/21/2024 | Non-covered Recipient Entity Accellacare US Inc | A PHASE 23 RANDOMIZED DOUBLEBLIND PLACEBO CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ORAL ZAVEGEPANT IN MIGRAINE PREVENTION | No dispute reported | 06/30/2026 | 1131051203 |
| Principal investigator 1 | BioNTech SE | $12,347.00 | 03/19/2024 | Non-covered Recipient Entity ACCELLACARE US INC | BNT163-01 | No dispute reported | 06/30/2026 | 1150667283 |
| Principal investigator 1 | BioNTech SE | $18,208.00 | 03/12/2024 | Non-covered Recipient Entity ACCELLACARE US INC | BNT163-01 | No dispute reported | 06/30/2026 | 1150667281 |
| Principal investigator 1 | BioNTech SE | $5,370.00 | 03/07/2024 | Non-covered Recipient Entity ACCELLACARE US INC | BNT163-01 | No dispute reported | 06/30/2026 | 1150667277 |
| Principal investigator 1 | Seqirus USA Inc | $1,000.00 | 03/06/2024 | Non-covered Recipient Entity Pmg Research | A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. | No dispute reported | 06/30/2026 | 1123459558 |
| Principal investigator 1 | Seqirus USA Inc | $853.00 | 03/06/2024 | Non-covered Recipient Entity Pmg Research | A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. | No dispute reported | 06/30/2026 | 1123459560 |
| Principal investigator 1 | Seqirus USA Inc | $2,000.00 | 03/06/2024 | Non-covered Recipient Entity Pmg Research | A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. | No dispute reported | 06/30/2026 | 1123459562 |
| Principal investigator 1 | Seqirus USA Inc | $6,000.00 | 03/06/2024 | Non-covered Recipient Entity Pmg Research | A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. | No dispute reported | 06/30/2026 | 1123459564 |
| Principal investigator 1 | Seqirus USA Inc | $23.98 | 03/04/2024 | Non-covered Recipient Entity Pmg Research | A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. | No dispute reported | 06/30/2026 | 1123459362 |
| Principal investigator 1 | Seqirus USA Inc | $95.49 | 03/04/2024 | Non-covered Recipient Entity Pmg Research | A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. | No dispute reported | 06/30/2026 | 1123459364 |
| Principal investigator 1 | Seqirus USA Inc | $38.36 | 03/04/2024 | Non-covered Recipient Entity Pmg Research | A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. | No dispute reported | 06/30/2026 | 1123459366 |
| Principal investigator 1 | Seqirus USA Inc | $131.11 | 03/04/2024 | Non-covered Recipient Entity Pmg Research | A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. | No dispute reported | 06/30/2026 | 1123459368 |
| Principal investigator 1 | Seqirus USA Inc | $95.49 | 03/04/2024 | Non-covered Recipient Entity Pmg Research | A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. | No dispute reported | 06/30/2026 | 1123459374 |
| Principal investigator 1 | Seqirus USA Inc | $95.49 | 03/04/2024 | Non-covered Recipient Entity Pmg Research | A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. | No dispute reported | 06/30/2026 | 1123459376 |
| Principal investigator 1 | Seqirus USA Inc | $38.36 | 03/04/2024 | Non-covered Recipient Entity Pmg Research | A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. | No dispute reported | 06/30/2026 | 1123459378 |
| Principal investigator 1 | Seqirus USA Inc | $23.98 | 03/04/2024 | Non-covered Recipient Entity Pmg Research | A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. | No dispute reported | 06/30/2026 | 1123459380 |
| Principal investigator 1 | Seqirus USA Inc | $38.36 | 03/04/2024 | Non-covered Recipient Entity Pmg Research | A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. | No dispute reported | 06/30/2026 | 1123459382 |
| Principal investigator 1 | Seqirus USA Inc | $131.11 | 03/04/2024 | Non-covered Recipient Entity Pmg Research | A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. | No dispute reported | 06/30/2026 | 1123459384 |
| Principal investigator 1 | Seqirus USA Inc | $23.98 | 03/04/2024 | Non-covered Recipient Entity Pmg Research | A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. | No dispute reported | 06/30/2026 | 1123459386 |
| Principal investigator 1 | Seqirus USA Inc | $23.98 | 03/04/2024 | Non-covered Recipient Entity Pmg Research | A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. | No dispute reported | 06/30/2026 | 1123459388 |
| Principal investigator 1 | Seqirus USA Inc | $23.98 | 03/04/2024 | Non-covered Recipient Entity Pmg Research | A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. | No dispute reported | 06/30/2026 | 1123459390 |
| Principal investigator 1 | Seqirus USA Inc | $213.58 | 03/04/2024 | Non-covered Recipient Entity Pmg Research | A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. | No dispute reported | 06/30/2026 | 1123459392 |
| Principal investigator 1 | Seqirus USA Inc | $95.49 | 03/04/2024 | Non-covered Recipient Entity Pmg Research | A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. | No dispute reported | 06/30/2026 | 1123459394 |
| Principal investigator 1 | Seqirus USA Inc | $38.36 | 03/04/2024 | Non-covered Recipient Entity Pmg Research | A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. | No dispute reported | 06/30/2026 | 1123459396 |
| Principal investigator 1 | Seqirus USA Inc | $131.11 | 03/04/2024 | Non-covered Recipient Entity Pmg Research | A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. | No dispute reported | 06/30/2026 | 1123459410 |
| Principal investigator 1 | Seqirus USA Inc | $131.11 | 03/04/2024 | Non-covered Recipient Entity Pmg Research | A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. | No dispute reported | 06/30/2026 | 1123459412 |
| Principal investigator 1 | Seqirus USA Inc | $213.58 | 03/04/2024 | Non-covered Recipient Entity Pmg Research | A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. | No dispute reported | 06/30/2026 | 1123459414 |
| Principal investigator 1 | Seqirus USA Inc | $38.36 | 03/04/2024 | Non-covered Recipient Entity Pmg Research | A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. | No dispute reported | 06/30/2026 | 1123459416 |
| Principal investigator 1 | Seqirus USA Inc | $23.98 | 03/04/2024 | Non-covered Recipient Entity Pmg Research | A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. | No dispute reported | 06/30/2026 | 1123459418 |
| Principal investigator 1 | Seqirus USA Inc | $131.11 | 03/04/2024 | Non-covered Recipient Entity Pmg Research | A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. | No dispute reported | 06/30/2026 | 1123459420 |
| Principal investigator 1 | Seqirus USA Inc | $38.36 | 03/04/2024 | Non-covered Recipient Entity Pmg Research | A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. | No dispute reported | 06/30/2026 | 1123459424 |
| Principal investigator 1 | Seqirus USA Inc | $38.36 | 03/04/2024 | Non-covered Recipient Entity Pmg Research | A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. | No dispute reported | 06/30/2026 | 1123459428 |
| Principal investigator 1 | Seqirus USA Inc | $38.36 | 03/04/2024 | Non-covered Recipient Entity Pmg Research | A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. | No dispute reported | 06/30/2026 | 1123459430 |
| Principal investigator 1 | Seqirus USA Inc | $95.49 | 03/04/2024 | Non-covered Recipient Entity Pmg Research | A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. | No dispute reported | 06/30/2026 | 1123459432 |
| Principal investigator 1 | Seqirus USA Inc | $95.49 | 03/04/2024 | Non-covered Recipient Entity Pmg Research | A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. | No dispute reported | 06/30/2026 | 1123459434 |
| Principal investigator 1 | Seqirus USA Inc | $23.98 | 03/04/2024 | Non-covered Recipient Entity Pmg Research | A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. | No dispute reported | 06/30/2026 | 1123459436 |
| Principal investigator 1 | Seqirus USA Inc | $213.58 | 03/04/2024 | Non-covered Recipient Entity Pmg Research | A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. | No dispute reported | 06/30/2026 | 1123459438 |
| Principal investigator 1 | Seqirus USA Inc | $23.98 | 03/04/2024 | Non-covered Recipient Entity Pmg Research | A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. | No dispute reported | 06/30/2026 | 1123459440 |
| Principal investigator 1 | Seqirus USA Inc | $95.49 | 03/04/2024 | Non-covered Recipient Entity Pmg Research | A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. | No dispute reported | 06/30/2026 | 1123459442 |
| Principal investigator 1 | Seqirus USA Inc | $95.49 | 03/04/2024 | Non-covered Recipient Entity Pmg Research | A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. | No dispute reported | 06/30/2026 | 1123459444 |
| Principal investigator 1 | Seqirus USA Inc | $213.58 | 03/04/2024 | Non-covered Recipient Entity Pmg Research | A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. | No dispute reported | 06/30/2026 | 1123459446 |
| Principal investigator 1 | Seqirus USA Inc | $95.49 | 03/04/2024 | Non-covered Recipient Entity Pmg Research | A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. | No dispute reported | 06/30/2026 | 1123459448 |
| Principal investigator 1 | Seqirus USA Inc | $38.36 | 03/04/2024 | Non-covered Recipient Entity Pmg Research | A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. | No dispute reported | 06/30/2026 | 1123459450 |
| Principal investigator 1 | Seqirus USA Inc | $38.36 | 03/04/2024 | Non-covered Recipient Entity Pmg Research | A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. | No dispute reported | 06/30/2026 | 1123459452 |
| Principal investigator 1 | Seqirus USA Inc | $131.11 | 03/04/2024 | Non-covered Recipient Entity Pmg Research | A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. | No dispute reported | 06/30/2026 | 1123459454 |
| Principal investigator 1 | Seqirus USA Inc | $38.36 | 03/04/2024 | Non-covered Recipient Entity Pmg Research | A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. | No dispute reported | 06/30/2026 | 1123459456 |
| Principal investigator 1 | Seqirus USA Inc | $95.49 | 03/04/2024 | Non-covered Recipient Entity Pmg Research | A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. | No dispute reported | 06/30/2026 | 1123459458 |
| Principal investigator 1 | Seqirus USA Inc | $23.98 | 03/04/2024 | Non-covered Recipient Entity Pmg Research | A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. | No dispute reported | 06/30/2026 | 1123459478 |
| Principal investigator 1 | Seqirus USA Inc | $95.49 | 03/04/2024 | Non-covered Recipient Entity Pmg Research | A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. | No dispute reported | 06/30/2026 | 1123459480 |
| Principal investigator 1 | Seqirus USA Inc | $131.11 | 03/04/2024 | Non-covered Recipient Entity Pmg Research | A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. | No dispute reported | 06/30/2026 | 1123459482 |
| Principal investigator 1 | Seqirus USA Inc | $23.98 | 03/04/2024 | Non-covered Recipient Entity Pmg Research | A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. | No dispute reported | 06/30/2026 | 1123459484 |
| Principal investigator 1 | Seqirus USA Inc | $213.58 | 03/04/2024 | Non-covered Recipient Entity Pmg Research | A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. | No dispute reported | 06/30/2026 | 1123459486 |
| Principal investigator 1 | Seqirus USA Inc | $38.36 | 03/04/2024 | Non-covered Recipient Entity Pmg Research | A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. | No dispute reported | 06/30/2026 | 1123459488 |
| Principal investigator 1 | Seqirus USA Inc | $95.49 | 03/04/2024 | Non-covered Recipient Entity Pmg Research | A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. | No dispute reported | 06/30/2026 | 1123459490 |
| Principal investigator 1 | Seqirus USA Inc | $131.11 | 03/04/2024 | Non-covered Recipient Entity Pmg Research | A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. | No dispute reported | 06/30/2026 | 1123459492 |
| Principal investigator 1 | Seqirus USA Inc | $213.58 | 03/04/2024 | Non-covered Recipient Entity Pmg Research | A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. | No dispute reported | 06/30/2026 | 1123459494 |
| Principal investigator 1 | Seqirus USA Inc | $23.98 | 03/04/2024 | Non-covered Recipient Entity Pmg Research | A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. | No dispute reported | 06/30/2026 | 1123459496 |
| Principal investigator 1 | Seqirus USA Inc | $131.11 | 03/04/2024 | Non-covered Recipient Entity Pmg Research | A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. | No dispute reported | 06/30/2026 | 1123459498 |
| Principal investigator 1 | Seqirus USA Inc | $95.49 | 03/04/2024 | Non-covered Recipient Entity Pmg Research | A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. | No dispute reported | 06/30/2026 | 1123459500 |
| Principal investigator 1 | Seqirus USA Inc | $23.98 | 03/04/2024 | Non-covered Recipient Entity Pmg Research | A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. | No dispute reported | 06/30/2026 | 1123459538 |
| Principal investigator 1 | Seqirus USA Inc | $23.98 | 03/04/2024 | Non-covered Recipient Entity Pmg Research | A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. | No dispute reported | 06/30/2026 | 1123459540 |
| Principal investigator 1 | Seqirus USA Inc | $131.11 | 03/04/2024 | Non-covered Recipient Entity Pmg Research | A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. | No dispute reported | 06/30/2026 | 1123459542 |
| Principal investigator 1 | Seqirus USA Inc | $95.49 | 03/04/2024 | Non-covered Recipient Entity Pmg Research | A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. | No dispute reported | 06/30/2026 | 1123459546 |
| Principal investigator 1 | Seqirus USA Inc | $131.11 | 03/04/2024 | Non-covered Recipient Entity Pmg Research | A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. | No dispute reported | 06/30/2026 | 1123459548 |
| Principal investigator 1 | Seqirus USA Inc | $95.49 | 03/04/2024 | Non-covered Recipient Entity Pmg Research | A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. | No dispute reported | 06/30/2026 | 1123459568 |
| Principal investigator 1 | Seqirus USA Inc | $95.49 | 03/04/2024 | Non-covered Recipient Entity Pmg Research | A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. | No dispute reported | 06/30/2026 | 1123459570 |
| Principal investigator 1 | Seqirus USA Inc | $38.36 | 03/04/2024 | Non-covered Recipient Entity Pmg Research | A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. | No dispute reported | 06/30/2026 | 1123459572 |
| Principal investigator 1 | Seqirus USA Inc | $95.49 | 03/04/2024 | Non-covered Recipient Entity Pmg Research | A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. | No dispute reported | 06/30/2026 | 1123459574 |
| Principal investigator 1 | Seqirus USA Inc | $38.36 | 03/04/2024 | Non-covered Recipient Entity Pmg Research | A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. | No dispute reported | 06/30/2026 | 1123459576 |
| Principal investigator 1 | Seqirus USA Inc | $38.36 | 03/04/2024 | Non-covered Recipient Entity Pmg Research | A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. | No dispute reported | 06/30/2026 | 1123459578 |
| Principal investigator 1 | Seqirus USA Inc | $38.36 | 03/04/2024 | Non-covered Recipient Entity Pmg Research | A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. | No dispute reported | 06/30/2026 | 1123459580 |
| Principal investigator 1 | Seqirus USA Inc | $95.49 | 03/04/2024 | Non-covered Recipient Entity Pmg Research | A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. | No dispute reported | 06/30/2026 | 1123459582 |
| Principal investigator 1 | Seqirus USA Inc | $95.49 | 03/04/2024 | Non-covered Recipient Entity Pmg Research | A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. | No dispute reported | 06/30/2026 | 1123459584 |
| Principal investigator 1 | Seqirus USA Inc | $213.58 | 03/04/2024 | Non-covered Recipient Entity Pmg Research | A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. | No dispute reported | 06/30/2026 | 1123459590 |
| Principal investigator 1 | Seqirus USA Inc | $213.58 | 03/04/2024 | Non-covered Recipient Entity Pmg Research | A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. | No dispute reported | 06/30/2026 | 1123459592 |
| Principal investigator 1 | Seqirus USA Inc | $23.98 | 03/04/2024 | Non-covered Recipient Entity Pmg Research | A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. | No dispute reported | 06/30/2026 | 1123459594 |
| Principal investigator 1 | Seqirus USA Inc | $23.98 | 03/04/2024 | Non-covered Recipient Entity Pmg Research | A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. | No dispute reported | 06/30/2026 | 1123459596 |
| Principal investigator 1 | Seqirus USA Inc | $38.36 | 03/04/2024 | Non-covered Recipient Entity Pmg Research | A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. | No dispute reported | 06/30/2026 | 1123459598 |
| Principal investigator 1 | Seqirus USA Inc | $213.58 | 03/04/2024 | Non-covered Recipient Entity Pmg Research | A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. | No dispute reported | 06/30/2026 | 1123459600 |
| Principal investigator 1 | Seqirus USA Inc | $95.49 | 03/04/2024 | Non-covered Recipient Entity Pmg Research | A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. | No dispute reported | 06/30/2026 | 1123459602 |
| Principal investigator 1 | Seqirus USA Inc | $95.49 | 03/04/2024 | Non-covered Recipient Entity Pmg Research | A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. | No dispute reported | 06/30/2026 | 1123459606 |
| Principal investigator 1 | Seqirus USA Inc | $38.36 | 03/04/2024 | Non-covered Recipient Entity Pmg Research | A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. | No dispute reported | 06/30/2026 | 1123459608 |
| Principal investigator 1 | Seqirus USA Inc | $95.49 | 03/04/2024 | Non-covered Recipient Entity Pmg Research | A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. | No dispute reported | 06/30/2026 | 1123459610 |
| Principal investigator 1 | Seqirus USA Inc | $95.49 | 03/04/2024 | Non-covered Recipient Entity Pmg Research | A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. | No dispute reported | 06/30/2026 | 1123459612 |
| Principal investigator 1 | Seqirus USA Inc | $95.49 | 03/04/2024 | Non-covered Recipient Entity Pmg Research | A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. | No dispute reported | 06/30/2026 | 1123459614 |
| Principal investigator 1 | Seqirus USA Inc | $213.58 | 03/04/2024 | Non-covered Recipient Entity Pmg Research | A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. | No dispute reported | 06/30/2026 | 1123459616 |
| Principal investigator 1 | Seqirus USA Inc | $23.98 | 03/04/2024 | Non-covered Recipient Entity Pmg Research | A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. | No dispute reported | 06/30/2026 | 1123459618 |
| Principal investigator 1 | Seqirus USA Inc | $95.49 | 03/04/2024 | Non-covered Recipient Entity Pmg Research | A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. | No dispute reported | 06/30/2026 | 1123459630 |
| Principal investigator 1 | Seqirus USA Inc | $38.36 | 03/04/2024 | Non-covered Recipient Entity Pmg Research | A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. | No dispute reported | 06/30/2026 | 1123459632 |
| Principal investigator 1 | Seqirus USA Inc | $95.49 | 03/04/2024 | Non-covered Recipient Entity Pmg Research | A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. | No dispute reported | 06/30/2026 | 1123459634 |
| Principal investigator 1 | Seqirus USA Inc | $95.49 | 03/04/2024 | Non-covered Recipient Entity Pmg Research | A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. | No dispute reported | 06/30/2026 | 1123459636 |
| Principal investigator 1 | Seqirus USA Inc | $38.36 | 03/04/2024 | Non-covered Recipient Entity Pmg Research | A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. | No dispute reported | 06/30/2026 | 1123459638 |
| Principal investigator 1 | Seqirus USA Inc | $23.98 | 03/04/2024 | Non-covered Recipient Entity Pmg Research | A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. | No dispute reported | 06/30/2026 | 1123459640 |
| Principal investigator 1 | Seqirus USA Inc | $95.49 | 03/04/2024 | Non-covered Recipient Entity Pmg Research | A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. | No dispute reported | 06/30/2026 | 1123459642 |
| Principal investigator 1 | Seqirus USA Inc | $95.49 | 03/04/2024 | Non-covered Recipient Entity Pmg Research | A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. | No dispute reported | 06/30/2026 | 1123459644 |
| Principal investigator 1 | Seqirus USA Inc | $131.11 | 03/04/2024 | Non-covered Recipient Entity Pmg Research | A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. | No dispute reported | 06/30/2026 | 1123459646 |
| Principal investigator 1 | Seqirus USA Inc | $23.98 | 03/04/2024 | Non-covered Recipient Entity Pmg Research | A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. | No dispute reported | 06/30/2026 | 1123459648 |
| Principal investigator 1 | Seqirus USA Inc | $95.49 | 03/04/2024 | Non-covered Recipient Entity Pmg Research | A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. | No dispute reported | 06/30/2026 | 1123459650 |
| Principal investigator 1 | Seqirus USA Inc | $23.98 | 03/04/2024 | Non-covered Recipient Entity Pmg Research | A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. | No dispute reported | 06/30/2026 | 1123459682 |
| Principal investigator 1 | Seqirus USA Inc | $38.36 | 03/04/2024 | Non-covered Recipient Entity Pmg Research | A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. | No dispute reported | 06/30/2026 | 1123459686 |
| Principal investigator 1 | Seqirus USA Inc | $38.36 | 03/04/2024 | Non-covered Recipient Entity Pmg Research | A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. | No dispute reported | 06/30/2026 | 1123459688 |
| Principal investigator 1 | Seqirus USA Inc | $23.98 | 03/04/2024 | Non-covered Recipient Entity Pmg Research | A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. | No dispute reported | 06/30/2026 | 1123459696 |
| Principal investigator 1 | Seqirus USA Inc | $23.98 | 03/04/2024 | Non-covered Recipient Entity Pmg Research | A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. | No dispute reported | 06/30/2026 | 1123459698 |
| Principal investigator 1 | Seqirus USA Inc | $95.49 | 03/04/2024 | Non-covered Recipient Entity Pmg Research | A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. | No dispute reported | 06/30/2026 | 1123459700 |
| Principal investigator 1 | Seqirus USA Inc | $23.98 | 03/04/2024 | Non-covered Recipient Entity Pmg Research | A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. | No dispute reported | 06/30/2026 | 1123459716 |
| Principal investigator 1 | Seqirus USA Inc | $213.58 | 03/04/2024 | Non-covered Recipient Entity Pmg Research | A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. | No dispute reported | 06/30/2026 | 1123459732 |
| Principal investigator 1 | Seqirus USA Inc | $23.98 | 03/04/2024 | Non-covered Recipient Entity Pmg Research | A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. | No dispute reported | 06/30/2026 | 1123459742 |
| Principal investigator 1 | Seqirus USA Inc | $95.49 | 03/04/2024 | Non-covered Recipient Entity Pmg Research | A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. | No dispute reported | 06/30/2026 | 1123459748 |
| Principal investigator 1 | Seqirus USA Inc | $95.49 | 03/04/2024 | Non-covered Recipient Entity Pmg Research | A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. | No dispute reported | 06/30/2026 | 1123459750 |
| Principal investigator 1 | Seqirus USA Inc | $95.49 | 03/04/2024 | Non-covered Recipient Entity Pmg Research | A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. | No dispute reported | 06/30/2026 | 1123459752 |
| Principal investigator 1 | Bavarian Nordic A/S | $2,597.00 | 02/29/2024 | Non-covered Recipient Entity ACCELLACARE US INC | A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age | No dispute reported | 06/30/2026 | 1119663878 |
| Principal investigator 1 | Bavarian Nordic A/S | $1,500.00 | 02/29/2024 | Non-covered Recipient Entity ACCELLACARE US INC | A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age | No dispute reported | 06/30/2026 | 1119663882 |
| Principal investigator 1 | Bavarian Nordic A/S | $2,064.00 | 02/29/2024 | Non-covered Recipient Entity ACCELLACARE US INC | A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age | No dispute reported | 06/30/2026 | 1119663894 |
| Principal investigator 1 | BioNTech SE | $693.00 | 02/29/2024 | Non-covered Recipient Entity ACCELLACARE US INC | BNT163-01 | No dispute reported | 06/30/2026 | 1150667291 |
| Principal investigator 1 | PFIZER INC. | $13,284.00 | 02/29/2024 | Non-covered Recipient Entity Accellacare US Inc | A PHASE 3 MASTER PROTOCOL TO EVALUATE ADDITIONAL DOSES OF BNT162B2 IN HEALTHY INDIVIDUALS PREVIOUSLY VACCINATED WITH BNT162B2 | No dispute reported | 06/30/2026 | 1131098395 |
| Principal investigator 1 | BioNTech SE | $693.00 | 02/21/2024 | Non-covered Recipient Entity ACCELLACARE US INC | BNT163-01 | No dispute reported | 06/30/2026 | 1150667287 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $8,247.90 | 02/21/2024 | Non-covered Recipient Entity ACCELLACARE US INC | A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA | No dispute reported | 06/30/2026 | 1127529597 |
| Principal investigator 1 | PFIZER INC. | $500.00 | 02/21/2024 | Non-covered Recipient Entity Accellacare US Inc | A PHASE 3 MASTER PROTOCOL TO EVALUATE ADDITIONAL DOSES OF BNT162B2 IN HEALTHY INDIVIDUALS PREVIOUSLY VACCINATED WITH BNT162B2 | No dispute reported | 06/30/2026 | 1131098402 |
| Principal investigator 1 | PFIZER INC. | $1,920.00 | 02/14/2024 | Non-covered Recipient Entity Accellacare US Inc | A PHASE 2B PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A HEXAVALENT GROUP B STREPTOCOCCUS VACCINE WHEN ADMINISTERED CONCOMITANTLY WITH TETANUS DIPHTHERIA AND ACELLULAR PERTUSSIS VACCINE TDAP IN HEALTHY NONPREGNANT WOMEN 18 THROUGH 49 YEARS OF AGE | No dispute reported | 06/30/2026 | 1131098543 |
| Principal investigator 1 | Bavarian Nordic A/S | $202.00 | 02/13/2024 | Non-covered Recipient Entity ACCELLACARE US INC | A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age | No dispute reported | 06/30/2026 | 1119663884 |
| Principal investigator 1 | Bavarian Nordic A/S | $40.00 | 02/13/2024 | Non-covered Recipient Entity ACCELLACARE US INC | A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age | No dispute reported | 06/30/2026 | 1119663890 |
| Principal investigator 1 | BioNTech SE | $48.00 | 02/13/2024 | Non-covered Recipient Entity ACCELLACARE US INC | BNT163-01 | No dispute reported | 06/30/2026 | 1150667293 |
| Principal investigator 1 | BioNTech SE | $900.00 | 02/13/2024 | Non-covered Recipient Entity ACCELLACARE US INC | BNT163-01 | No dispute reported | 06/30/2026 | 1150667295 |
| Principal investigator 1 | BioNTech SE | $300.00 | 02/13/2024 | Non-covered Recipient Entity ACCELLACARE US INC | BNT163-01 | No dispute reported | 06/30/2026 | 1150667297 |
| Principal investigator 1 | BioNTech SE | $96.00 | 02/13/2024 | Non-covered Recipient Entity ACCELLACARE US INC | BNT163-01 | No dispute reported | 06/30/2026 | 1150667303 |
| Principal investigator 1 | BioNTech SE | $1,386.00 | 01/31/2024 | Non-covered Recipient Entity ACCELLACARE US INC | BNT163-01 | No dispute reported | 06/30/2026 | 1150667285 |
| Principal investigator 1 | Eli Lilly and Company | $2,480.40 | 01/31/2024 | Non-covered Recipient Entity RHEUMATOLOGY CENTER OF HOUSTON | A PHASE 3 RANDOMIZED DOUBLE BLIND STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ONCE DAILY ORAL LY3502970 COMPARED WITH PLACEBO IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT AND TYPE 2 DIABETES (ATTAIN-2) | No dispute reported | 06/30/2026 | 1137366665 |
| Principal investigator 1 | PFIZER INC. | $24,344.25 | 01/27/2024 | Non-covered Recipient Entity PMG Research Inc | A 26WEEK PHASE 2B 2PART RANDOMIZED DOUBLEBLIND PLACEBO CONTROLLED PARALLEL GROUP DOSERANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF06882961 ADMINISTRATION IN ADULTS WITH OBESITY | No dispute reported | 06/30/2026 | 1131108237 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $16,148.10 | 01/24/2024 | Non-covered Recipient Entity ACCELLACARE US INC | A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA | No dispute reported | 06/30/2026 | 1127527052 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $500.00 | 01/24/2024 | Non-covered Recipient Entity PIEDMONT MEDICAL RESEARCH PMG RESEARCH | A Randomized Double-blind, Placebo-controlled, Multicenter Trial Assessing the Impact of Lipoprotein (a) Lowering With TQJ230 on Major Cardiovascular Events in Patients With Established Cardiovascular Disease | No dispute reported | 06/30/2026 | 1089694905 |
| Principal investigator 1 | PFIZER INC. | $5,356.70 | 01/24/2024 | Non-covered Recipient Entity Accellacare US Inc | A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER | No dispute reported | 06/30/2026 | 1131106617 |
| Principal investigator 1 | Bavarian Nordic A/S | $11,262.00 | 01/23/2024 | Non-covered Recipient Entity ACCELLACARE US INC | A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age | No dispute reported | 06/30/2026 | 1119663886 |
| Principal investigator 1 | Bavarian Nordic A/S | $1,579.00 | 01/23/2024 | Non-covered Recipient Entity ACCELLACARE US INC | A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age | No dispute reported | 06/30/2026 | 1119663888 |
| Principal investigator 1 | Bavarian Nordic A/S | $15,000.00 | 01/23/2024 | Non-covered Recipient Entity ACCELLACARE US INC | A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age | No dispute reported | 06/30/2026 | 1119663896 |
| Principal investigator 1 | PFIZER INC. | $2,080.88 | 01/18/2024 | Non-covered Recipient Entity ACELLACARE US INC | A PHASE 23 RANDOMIZED DOUBLEBLIND PLACEBO CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ORAL ZAVEGEPANT IN MIGRAINE PREVENTION | No dispute reported | 06/30/2026 | 1131048659 |
| Principal investigator 1 | PFIZER INC. | $157,947.30 | 01/17/2024 | Non-covered Recipient Entity Accellacare US Inc | A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER | No dispute reported | 06/30/2026 | 1131108961 |
| Principal investigator 1 | BioNTech SE | $2,118.00 | 01/16/2024 | Non-covered Recipient Entity ACCELLACARE US INC | BNT163-01 | No dispute reported | 06/30/2026 | 1150667301 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $223.63 | 01/15/2024 | Non-covered Recipient Entity PMG RESEARCH OF RALEIGH | A Randomized Double-blind, Placebo-controlled, Multicenter Trial Assessing the Impact of Lipoprotein (a) Lowering With TQJ230 on Major Cardiovascular Events in Patients With Established Cardiovascular Disease | No dispute reported | 06/30/2026 | 1089688735 |
| Principal investigator 1 | BioNTech SE | $1,386.00 | 01/09/2024 | Non-covered Recipient Entity ACCELLACARE US INC | BNT163-01 | No dispute reported | 06/30/2026 | 1150667279 |
| Principal investigator 1 | Bavarian Nordic A/S | $371.00 | 01/05/2024 | Non-covered Recipient Entity ACCELLACARE US INC | A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age | No dispute reported | 06/30/2026 | 1119663876 |
| Principal investigator 1 | Bavarian Nordic A/S | $1,057.00 | 01/05/2024 | Non-covered Recipient Entity ACCELLACARE US INC | A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age | No dispute reported | 06/30/2026 | 1119663880 |
| Principal investigator 1 | Bavarian Nordic A/S | $516.00 | 01/05/2024 | Non-covered Recipient Entity ACCELLACARE US INC | A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age | No dispute reported | 06/30/2026 | 1119663892 |
| Principal investigator 1 | Bavarian Nordic A/S | $371.00 | 01/05/2024 | Non-covered Recipient Entity ACCELLACARE US INC | A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age | No dispute reported | 06/30/2026 | 1119663898 |
| Principal investigator 1 | BioNTech SE | $3,601.00 | 01/05/2024 | Non-covered Recipient Entity ACCELLACARE US INC | BNT163-01 | No dispute reported | 06/30/2026 | 1150667275 |
| Principal investigator 1 | BioNTech SE | $300.00 | 01/05/2024 | Non-covered Recipient Entity ACCELLACARE US INC | BNT163-01 | No dispute reported | 06/30/2026 | 1150667299 |
| Principal investigator 1 | Eli Lilly and Company | $253,217.00 | 01/02/2024 | Non-covered Recipient Entity PIEDMONT MEDICAL RESEARCH ASSOCIATES INC | A PHASE 3 RANDOMIZED DOUBLE BLIND STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ONCE DAILY ORAL LY3502970 COMPARED WITH PLACEBO IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT AND TYPE 2 DIABETES (ATTAIN-2) | No dispute reported | 06/30/2026 | 1137365099 |